Clinical Sequencing of Cancer and Tissue Repository: ClinOmics View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2019-2035

ABSTRACT

Background: Saliva, blood, tissue, and cancer contain DNA. DNA makes the "instruction book" for the cells in the body. Cancer is caused by changes in DNA that affect cell function. Researchers want to test DNA of people with tumors. They want to look for genetic changes in tumors that could be targets for treatment. Because DNA can change as cancer changes, more testing may be done at different times. Objectives: To find the DNA changes in cancer that may help guide treatment. To collect samples and data to be used in future studies. Eligibility: People any age with cancer or a pre-cancerous tumor Design: - Participants will be screened with a medical history, physical exam, and blood tests. Participants will give a sample of their tumor. This is usually from a previous procedure. Participants will give a saliva or blood sample. They cannot eat, drink, smoke, or chew gum for 30 minutes before giving saliva. They will spit about 1 teaspoon of saliva into a tube. - Some participants may have a punch biopsy instead. A small instrument will take a small piece of skin. - Researchers will collect data from participants medical records. - Participants will answer questions about their family health history. They will also answer questions about their views on the study, including possible unexpected results. - Extra blood or tissue samples may be taken at other times during the participants' treatment. All samples will be saved in secure ClinOmics freezers to be used in future studies. - Participants will be told by their doctors if any test results affect their health or their cancer treatment. Detailed Description Background: - Laboratory-based investigations have contributed to an improved understanding of the biology of cancer and to the development of new therapies for malignancies. - Omics investigation may identify novel drivers in the germline or tumor for high risk, relapsed, refractory or rare cancers. - Omics investigation may identify germline or somatic alterations that are medically actionable and or can enable precision therapy. Objectives - Primary Objective: -Identify incidental and secondary findings in germline DNA and actionable somatic mutations for reporting clinical results from a CLIA-certified lab into CRIS medical records. Eligibility - Adult or Pediatric patients of any age with one of the following: - Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected cancer susceptibility familial syndromes, regardless of patient age; OR - Individuals without history of malignancy who are undergoing surgery; OR - Individuals without a history of cancer but evidence of an inherited cancer syndrome based on family history and/or other manifestations of a pre-cancerous syndrome (e.g. polyposis, plexiform neurofibromas, myelodysplastic disease); OR - Patient enrolled in an approved companion protocol. - Tissue (including tumor, normal, blood, bone marrow, serum, plasma, or other tissues) that has been previously collected under CLIA and maintained in a CLIA lab which is available for CLIA analysis. - Tissue (including tumor, normal, blood, bone marrow, serum, plasma, or other tissues) that has been previously collected and is available for research analysis. - Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care. - Individual may be undergoing treatment for malignancy, premalignant condition or receiving other care associated with an inherited cancer syndrome. - Patients may be referred to the Principal Investigator from outside institutions. - Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent OR - IRB waiver of the requirement for informed consent for specific types of tissue. Design: - This study will allow for the collection of specimens for CLIA reporting of germline and somatic mutations. The study will also collect specimens for a Tissue Repository, and for other investigations as outlined below. - CLIA testing activities will include - DNA extracted from a section of tumor, malignant tissue, blood, or bone marrow samples for somatic mutation sequence analysis - Germline DNA extracted from lymphocytes, saliva, skin, or any normal uninvolved tissues for sequence analysis to identify somatic alterations in the cancer and for the reporting of incidental findings of established clinical validity and utility. - Research activities may include: - DNA, RNA and protein Omics analyses from extracted normal and/or tumor tissues; the remainder of the tumor tissue will be stored. - Germline DNA and RNA analyses from extracted lymphocytes or other normal uninvolved tissue. - T (TCR) or B Cell Receptor sequencing from blood, tumor, or malignant tissue. - Establishing Patient-Derived Models such as patient-derived xenografts (PDXs), early-passage in vitro tumor cultures, and organoid cultures, conditionally reprogrammed cells (CRC) lines, explant and cell lines from tumor or normal samples by the NCI Patient-Derived Models Repository (PDMR) at Frederick National Laboratory for Cancer Research or by the OncoGenomics laboratory. - Cryopreservation of viable normal (e.g. PBMC) or malignant tissues. - Establishment of EBV transformed cell lines from blood for medical research either by Coriell Institute or by investigators on this protocol. - Omics (Genomics, Proteomic, Epigenetics, Metabolomics) studies will be performed. - Expected accrual 50-500 patients per year. Total protocol accrual goal 5,000 patients. More... »

URL

https://clinicaltrials.gov/show/NCT03027401

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Background: Saliva, blood, tissue, and cancer contain DNA. DNA makes the \"instruction book\" for the cells in the body. Cancer is caused by changes in DNA that affect cell function. Researchers want to test DNA of people with tumors. They want to look for genetic changes in tumors that could be targets for treatment. Because DNA can change as cancer changes, more testing may be done at different times. Objectives: To find the DNA changes in cancer that may help guide treatment. To collect samples and data to be used in future studies. Eligibility: People any age with cancer or a pre-cancerous tumor Design: - Participants will be screened with a medical history, physical exam, and blood tests. Participants will give a sample of their tumor. This is usually from a previous procedure. Participants will give a saliva or blood sample. They cannot eat, drink, smoke, or chew gum for 30 minutes before giving saliva. They will spit about 1 teaspoon of saliva into a tube. - Some participants may have a punch biopsy instead. A small instrument will take a small piece of skin. - Researchers will collect data from participants medical records. - Participants will answer questions about their family health history. They will also answer questions about their views on the study, including possible unexpected results. - Extra blood or tissue samples may be taken at other times during the participants' treatment. All samples will be saved in secure ClinOmics freezers to be used in future studies. - Participants will be told by their doctors if any test results affect their health or their cancer treatment.\n\nDetailed Description\nBackground: - Laboratory-based investigations have contributed to an improved understanding of the biology of cancer and to the development of new therapies for malignancies. - Omics investigation may identify novel drivers in the germline or tumor for high risk, relapsed, refractory or rare cancers. - Omics investigation may identify germline or somatic alterations that are medically actionable and or can enable precision therapy. Objectives - Primary Objective: -Identify incidental and secondary findings in germline DNA and actionable somatic mutations for reporting clinical results from a CLIA-certified lab into CRIS medical records. Eligibility - Adult or Pediatric patients of any age with one of the following: - Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected cancer susceptibility familial syndromes, regardless of patient age; OR - Individuals without history of malignancy who are undergoing surgery; OR - Individuals without a history of cancer but evidence of an inherited cancer syndrome based on family history and/or other manifestations of a pre-cancerous syndrome (e.g. polyposis, plexiform neurofibromas, myelodysplastic disease); OR - Patient enrolled in an approved companion protocol. - Tissue (including tumor, normal, blood, bone marrow, serum, plasma, or other tissues) that has been previously collected under CLIA and maintained in a CLIA lab which is available for CLIA analysis. - Tissue (including tumor, normal, blood, bone marrow, serum, plasma, or other tissues) that has been previously collected and is available for research analysis. - Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care. - Individual may be undergoing treatment for malignancy, premalignant condition or receiving other care associated with an inherited cancer syndrome. - Patients may be referred to the Principal Investigator from outside institutions. - Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent OR - IRB waiver of the requirement for informed consent for specific types of tissue. Design: - This study will allow for the collection of specimens for CLIA reporting of germline and somatic mutations. The study will also collect specimens for a Tissue Repository, and for other investigations as outlined below. - CLIA testing activities will include - DNA extracted from a section of tumor, malignant tissue, blood, or bone marrow samples for somatic mutation sequence analysis - Germline DNA extracted from lymphocytes, saliva, skin, or any normal uninvolved tissues for sequence analysis to identify somatic alterations in the cancer and for the reporting of incidental findings of established clinical validity and utility. - Research activities may include: - DNA, RNA and protein Omics analyses from extracted normal and/or tumor tissues; the remainder of the tumor tissue will be stored. - Germline DNA and RNA analyses from extracted lymphocytes or other normal uninvolved tissue. - T (TCR) or B Cell Receptor sequencing from blood, tumor, or malignant tissue. - Establishing Patient-Derived Models such as patient-derived xenografts (PDXs), early-passage in vitro tumor cultures, and organoid cultures, conditionally reprogrammed cells (CRC) lines, explant and cell lines from tumor or normal samples by the NCI Patient-Derived Models Repository (PDMR) at Frederick National Laboratory for Cancer Research or by the OncoGenomics laboratory. - Cryopreservation of viable normal (e.g. PBMC) or malignant tissues. - Establishment of EBV transformed cell lines from blood for medical research either by Coriell Institute or by investigators on this protocol. - Omics (Genomics, Proteomic, Epigenetics, Metabolomics) studies will be performed. - Expected accrual 50-500 patients per year. Total protocol accrual goal 5,000 patients.", 
    "endDate": "2035-08-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03027401", 
    "keywords": [
      "laboratory-based investigation", 
      "somatic alteration", 
      "RNA", 
      "reporting", 
      "transformed cell line", 
      "lymphocyte", 
      "cell line", 
      "clinical validity", 
      "cell", 
      "clinical result", 
      "bone marrow", 
      "health", 
      "somatic mutation", 
      "eligibility", 
      "cancer treatment", 
      "omics", 
      "Neoplasm", 
      "specimen", 
      "DNA change", 
      "section", 
      "General Surgery", 
      "medical record", 
      "protocol", 
      "family history", 
      "medical history", 
      "institution", 
      "cryopreservation", 
      "malignant disorder", 
      "different time", 
      "sample", 
      "plexiform neurofibroma", 
      "future study", 
      "protein", 
      "Hematologic Test", 
      "Institute", 
      "improved understanding", 
      "patient age", 
      "cancer susceptibility", 
      "incidental finding", 
      "high risk", 
      "freezer", 
      "disease", 
      "pediatric patient", 
      "physical exam", 
      "malignant tissue", 
      "biology", 
      "principal investigator", 
      "written informed consent", 
      "target", 
      "collection", 
      "age", 
      "drink", 
      "sequencing", 
      "reprogrammed cell", 
      "polyposis", 
      "B cell receptor", 
      "small piece", 
      "establishment", 
      "driver", 
      "willingness", 
      "Book", 
      "PBMC", 
      "smoke", 
      "waiver", 
      "germline", 
      "culture", 
      "utility", 
      "Gingiva", 
      "explants", 
      "biopsy", 
      "specific type", 
      "patient", 
      "rare cancer", 
      "family health history", 
      "inherited cancer syndrome", 
      "DNA and RNA", 
      "germline DNA", 
      "testing activity", 
      "tissue sample", 
      "bone marrow sample", 
      "biospecimens", 
      "blood sample", 
      "cell function", 
      "answer question", 
      "remainder", 
      "evidence", 
      "CLIA", 
      "individual", 
      "teaspoon", 
      "tissue", 
      "body", 
      "laboratory", 
      "skin", 
      "early passage", 
      "tube", 
      "national laboratory", 
      "patient care", 
      "manifestation", 
      "serum", 
      "plasma", 
      "history", 
      "genetic change", 
      "precision", 
      "tissue repository", 
      "cancerous tumor", 
      "unexpected result", 
      "instrument", 
      "Identify", 
      "informed consent", 
      "sequence analysis", 
      "method", 
      "development", 
      "diagnosis", 
      "premalignant condition", 
      "Epigenomics", 
      "Biomedical Research", 
      "guide treatment", 
      "syndrome", 
      "malignancy", 
      "research analysis", 
      "DNA", 
      "repository", 
      "Research", 
      "saliva", 
      "tumor tissue", 
      "genomics", 
      "additional risk", 
      "metabolomics", 
      "sampling", 
      "derived model", 
      "therapy", 
      "LAR", 
      "blood", 
      "doctor", 
      "TCR", 
      "accrual", 
      "normal sample"
    ], 
    "name": "Clinical Sequencing of Cancer and Tissue Repository: ClinOmics", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03027401"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00023.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.48336.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2019-02-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1093/aje/kwu217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000241346"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/gim.2013.73", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017226766", 
          "https://doi.org/10.1038/gim.2013.73"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/gim.2013.145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053264915", 
          "https://doi.org/10.1038/gim.2013.145"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03027401"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03027401'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03027401'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03027401'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03027401'


 

This table displays all metadata directly associated to this object as RDF triples.

169 TRIPLES      16 PREDICATES      156 URIs      146 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03027401 schema:about anzsrc-for:3142
2 schema:description Background: Saliva, blood, tissue, and cancer contain DNA. DNA makes the "instruction book" for the cells in the body. Cancer is caused by changes in DNA that affect cell function. Researchers want to test DNA of people with tumors. They want to look for genetic changes in tumors that could be targets for treatment. Because DNA can change as cancer changes, more testing may be done at different times. Objectives: To find the DNA changes in cancer that may help guide treatment. To collect samples and data to be used in future studies. Eligibility: People any age with cancer or a pre-cancerous tumor Design: - Participants will be screened with a medical history, physical exam, and blood tests. Participants will give a sample of their tumor. This is usually from a previous procedure. Participants will give a saliva or blood sample. They cannot eat, drink, smoke, or chew gum for 30 minutes before giving saliva. They will spit about 1 teaspoon of saliva into a tube. - Some participants may have a punch biopsy instead. A small instrument will take a small piece of skin. - Researchers will collect data from participants medical records. - Participants will answer questions about their family health history. They will also answer questions about their views on the study, including possible unexpected results. - Extra blood or tissue samples may be taken at other times during the participants' treatment. All samples will be saved in secure ClinOmics freezers to be used in future studies. - Participants will be told by their doctors if any test results affect their health or their cancer treatment. Detailed Description Background: - Laboratory-based investigations have contributed to an improved understanding of the biology of cancer and to the development of new therapies for malignancies. - Omics investigation may identify novel drivers in the germline or tumor for high risk, relapsed, refractory or rare cancers. - Omics investigation may identify germline or somatic alterations that are medically actionable and or can enable precision therapy. Objectives - Primary Objective: -Identify incidental and secondary findings in germline DNA and actionable somatic mutations for reporting clinical results from a CLIA-certified lab into CRIS medical records. Eligibility - Adult or Pediatric patients of any age with one of the following: - Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected cancer susceptibility familial syndromes, regardless of patient age; OR - Individuals without history of malignancy who are undergoing surgery; OR - Individuals without a history of cancer but evidence of an inherited cancer syndrome based on family history and/or other manifestations of a pre-cancerous syndrome (e.g. polyposis, plexiform neurofibromas, myelodysplastic disease); OR - Patient enrolled in an approved companion protocol. - Tissue (including tumor, normal, blood, bone marrow, serum, plasma, or other tissues) that has been previously collected under CLIA and maintained in a CLIA lab which is available for CLIA analysis. - Tissue (including tumor, normal, blood, bone marrow, serum, plasma, or other tissues) that has been previously collected and is available for research analysis. - Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care. - Individual may be undergoing treatment for malignancy, premalignant condition or receiving other care associated with an inherited cancer syndrome. - Patients may be referred to the Principal Investigator from outside institutions. - Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent OR - IRB waiver of the requirement for informed consent for specific types of tissue. Design: - This study will allow for the collection of specimens for CLIA reporting of germline and somatic mutations. The study will also collect specimens for a Tissue Repository, and for other investigations as outlined below. - CLIA testing activities will include - DNA extracted from a section of tumor, malignant tissue, blood, or bone marrow samples for somatic mutation sequence analysis - Germline DNA extracted from lymphocytes, saliva, skin, or any normal uninvolved tissues for sequence analysis to identify somatic alterations in the cancer and for the reporting of incidental findings of established clinical validity and utility. - Research activities may include: - DNA, RNA and protein Omics analyses from extracted normal and/or tumor tissues; the remainder of the tumor tissue will be stored. - Germline DNA and RNA analyses from extracted lymphocytes or other normal uninvolved tissue. - T (TCR) or B Cell Receptor sequencing from blood, tumor, or malignant tissue. - Establishing Patient-Derived Models such as patient-derived xenografts (PDXs), early-passage in vitro tumor cultures, and organoid cultures, conditionally reprogrammed cells (CRC) lines, explant and cell lines from tumor or normal samples by the NCI Patient-Derived Models Repository (PDMR) at Frederick National Laboratory for Cancer Research or by the OncoGenomics laboratory. - Cryopreservation of viable normal (e.g. PBMC) or malignant tissues. - Establishment of EBV transformed cell lines from blood for medical research either by Coriell Institute or by investigators on this protocol. - Omics (Genomics, Proteomic, Epigenetics, Metabolomics) studies will be performed. - Expected accrual 50-500 patients per year. Total protocol accrual goal 5,000 patients.
3 schema:endDate 2035-08-01T00:00:00Z
4 schema:keywords B cell receptor
5 Biomedical Research
6 Book
7 CLIA
8 DNA
9 DNA and RNA
10 DNA change
11 Epigenomics
12 General Surgery
13 Gingiva
14 Hematologic Test
15 Identify
16 Institute
17 LAR
18 Neoplasm
19 PBMC
20 RNA
21 Research
22 TCR
23 accrual
24 additional risk
25 age
26 answer question
27 biology
28 biopsy
29 biospecimens
30 blood
31 blood sample
32 body
33 bone marrow
34 bone marrow sample
35 cancer susceptibility
36 cancer treatment
37 cancerous tumor
38 cell
39 cell function
40 cell line
41 clinical result
42 clinical validity
43 collection
44 cryopreservation
45 culture
46 derived model
47 development
48 diagnosis
49 different time
50 disease
51 doctor
52 drink
53 driver
54 early passage
55 eligibility
56 establishment
57 evidence
58 explants
59 family health history
60 family history
61 freezer
62 future study
63 genetic change
64 genomics
65 germline
66 germline DNA
67 guide treatment
68 health
69 high risk
70 history
71 improved understanding
72 incidental finding
73 individual
74 informed consent
75 inherited cancer syndrome
76 institution
77 instrument
78 laboratory
79 laboratory-based investigation
80 lymphocyte
81 malignancy
82 malignant disorder
83 malignant tissue
84 manifestation
85 medical history
86 medical record
87 metabolomics
88 method
89 national laboratory
90 normal sample
91 omics
92 patient
93 patient age
94 patient care
95 pediatric patient
96 physical exam
97 plasma
98 plexiform neurofibroma
99 polyposis
100 precision
101 premalignant condition
102 principal investigator
103 protein
104 protocol
105 rare cancer
106 remainder
107 reporting
108 repository
109 reprogrammed cell
110 research analysis
111 saliva
112 sample
113 sampling
114 section
115 sequence analysis
116 sequencing
117 serum
118 skin
119 small piece
120 smoke
121 somatic alteration
122 somatic mutation
123 specific type
124 specimen
125 syndrome
126 target
127 teaspoon
128 testing activity
129 therapy
130 tissue
131 tissue repository
132 tissue sample
133 transformed cell line
134 tube
135 tumor tissue
136 unexpected result
137 utility
138 waiver
139 willingness
140 written informed consent
141 schema:name Clinical Sequencing of Cancer and Tissue Repository: ClinOmics
142 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03027401
143 schema:sdDatePublished 2019-03-07T15:27
144 schema:sdLicense https://scigraph.springernature.com/explorer/license/
145 schema:sdPublisher N71b56e803f1f4e21abb44f9c2d39208b
146 schema:sponsor https://www.grid.ac/institutes/grid.410305.3
147 https://www.grid.ac/institutes/grid.48336.3a
148 schema:startDate 2019-02-01T00:00:00Z
149 schema:subjectOf sg:pub.10.1038/gim.2013.145
150 sg:pub.10.1038/gim.2013.73
151 https://doi.org/10.1093/aje/kwu217
152 schema:url https://clinicaltrials.gov/show/NCT03027401
153 sgo:license sg:explorer/license/
154 sgo:sdDataset clinical_trials
155 rdf:type schema:MedicalStudy
156 N71b56e803f1f4e21abb44f9c2d39208b schema:name Springer Nature - SN SciGraph project
157 rdf:type schema:Organization
158 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
159 rdf:type schema:DefinedTerm
160 sg:pub.10.1038/gim.2013.145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053264915
161 https://doi.org/10.1038/gim.2013.145
162 rdf:type schema:CreativeWork
163 sg:pub.10.1038/gim.2013.73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017226766
164 https://doi.org/10.1038/gim.2013.73
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1093/aje/kwu217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000241346
167 rdf:type schema:CreativeWork
168 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
169 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...